High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 406-414

  Lossos, Izidore S ^a,b   Hosein, Peter J ^a   Morgensztern, Daniel ^a   Coleman, Francine ^a   Escalón, Maricer P ^a   Byrne Jr , Gerald E ^b   Rosenblatt, Joseph D ^a   Walker, Gail R ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Chemotherapy; Mantle cell lymphoma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MESNA; METHOTREXATE; RITUXIMAB; THALIDOMIDE; VINCRISTINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ERECTILE DYSFUNCTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MULTICENTER STUDY; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, MANTLE-CELL; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 77249120575     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903518345     Document Type: Article

References (25)

1. Swerdlow SH, Campo E,Harris NL, et al.WHOclassification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
2. Dreyling M, Hiddemann W. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Curr Opin Oncol 2008;20:487-494.
3. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in adVan ced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
4. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803-3809.
5. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper- CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
6. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257-262.
7. Van Denberghe E, De Wolf-Peeters C, Vaughan Hudson G, et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997;99:842-847.
8. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992.
9. Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005;23:6364-6369.
10. Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001;13: 342-347.
11. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in adVan ced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385-2387.
12. Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 2009;115:1041-1048.
13. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-197.
14. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925-934.
15. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/ refractory mantle cell lymphoma. Blood 2004;104:2269-2271.
16. Carbone PP, Kaplan HS, Musshoff K, et al. Report on the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
18. Collett D. Modelling survival data in medical research. London: Chapman & Hall; 1994. p. 26.
19. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. New York: John Wiley; 1996.
20. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0, 2003. Available from: http://ctep.cancer. gov/reporting/ctc.html.
21. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with adVan ced-stage mantle cell lymphoma. Blood 2008;111:558-565.
22. Epner EM, Unger J, Miller T, et al. A multicenter trial of hyperCVAD + Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007;110(Suppl. 1):121a (Abstract 387).
23. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression- free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
24. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-349.
25. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008;112:2248-2260.